CMS Acting Administrator calls for more drug pricing transparency: 3 notes

CMS Acting Administrator Andy Slavitt called for increased transparency regarding drug pricing at the HHS Pharmaceutical Forum, according to an AHA News report.

Here are three notes, from Mr. Slavitt's comments:

1. Mr. Slavitt noted that there isn't "enough public information on the effectiveness of new drugs in the real world or about prices and rebate structures."

2. He also stated that a common understanding of the drug pricing data does not exist, making it harder to sift through the various costs associated with medications, such as list prices, wholesale prices, average wholesale prices, rebates, supplemental rebates, etc.

3. Mr. Slavitt notes that increasing the transparency of drug pricing and value information is necessary to prevent reactions to misinformation.

Learn more about key strategies & technologies for efficient, cost-effective ASCs — Click here!

Copyright © 2022 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


Featured Webinars

Featured Whitepapers

Featured Podcast